



Contents lists available at ScienceDirect

Acta Histochemica

journal homepage: www.elsevier.de/acthis



Review

Wharton's jelly derived mesenchymal stromal cells: Biological properties, induction of neuronal phenotype and current applications in neurodegeneration research

Stefano Frausin^{a,1}, Serena Viventi^{a,1}, Lucia Verga Falzacappa^a,
Miriana Jlenia Quattromani^a, Giampiero Leanza^a, Alberto Tommasini^b, Erica Valencic^{b,*}

^a B.R.A.I.N. Lab for Neurogenesis and Repair, Department Life Sciences, University of Trieste, Italy

^b Immunopathology Lab, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy

ARTICLE INFO

Article history:

Available online xxx

Keywords:

Mesenchymal stem cells
Wharton's jelly
Neural differentiation
Peripheral nerve regeneration
Amyotrophic lateral sclerosis
Neuroprotection

ABSTRACT

Multipotent mesenchymal stromal cells, also known as mesenchymal stem cells (MSC), can be isolated from bone marrow or other tissues, including fat, muscle and umbilical cord. It has been shown that MSC behave *in vitro* as stem cells: they self-renew and are able to differentiate into mature cells typical of several mesenchymal tissues. Moreover, the differentiation toward non-mesenchymal cell lineages (e.g. neurons) has been reported as well. The clinical relevance of these cells is mainly related to their ability to spontaneously migrate to the site of inflammation/damage, to their safety profile thanks to their low immunogenicity and to their immunomodulation capacities. To date, MSCs isolated from the post-natal bone marrow have represented the most extensively studied population of adult MSCs, in view of their possible use in various therapeutical applications. However, the bone marrow-derived MSCs exhibit a series of limitations, mainly related to their problematic isolation, culturing and use. In recent years, umbilical cord (UC) matrix (*i.e.* Wharton's jelly, WJ) stromal cells have therefore emerged as a more suitable alternative source of MSCs, thanks to their primitive nature and the easy isolation without relevant ethical concerns. This review seeks to provide an overview of the main biological properties of WJ-derived MSCs. Moreover, the potential application of these cells for the treatment of some known dysfunctions in the central and peripheral nervous system will also be discussed.

© 2015 Elsevier GmbH. All rights reserved.

Introduction

Mesenchymal stromal cells (MSC) from bone marrow have initially gained much attention by hematologists involved in hematopoietic stem cell transplantation. However, it soon became

clear that MSCs have biological properties making them suitable for use in regenerative medicine and immunomodulation. Moreover, MSCs obtained from other sources could offer theoretical advantages over bone marrow derived ones. In particular, MSC derived from the Wharton's jelly of the umbilical cord (WJM-SCs) exhibit unique features (e.g. primitive nature, multilineage potential immunomodulatory ability, ease of isolation, extensive proliferation) that may make them more valuable therapeutic tools for the treatment of various diseases or tissue damage. This review will first attempt to provide a brief summary of the main biological properties of WJM-SCs, and then discuss their efficacy to promote anatomical and functional recovery upon transplantation in rodent models of central and peripheral nerve dysfunction.

Isolation, characterization and growth of mesenchymal stromal cells

Multipotent mesenchymal stromal cells (MSC), also known as mesenchymal stem cells (MSC) were first isolated from animal bone marrow by [Friedenstein et al. \(1970\)](#) and were initially described

Abbreviations: WJ, Wharton's jelly; UC, umbilical cord; MSC, mesenchymal stromal (stem) cells; WJM-SC, Wharton's jelly mesenchymal stromal cells; HLA, human leukocyte antigen; HSC, hematopoietic stem cells; GvHD, graft versus host disease; NK, natural killer; TNF, tumor necrosis factor; IFN, interferon; bFGF, basic fibroblast growth factor; BHA, butylated hydroxy-anisole; DMSO, di-methyl-sulf-oxide; RA, retinoid acid; NGF, nerve growth factor; FCS, fetal calf serum; NCM, neuronal conditioned medium; NIM, neuronal induction medium; BDNF, brain derived neurotrophic factor; EGF, epidermal growth factor; NFM, neurofilament M; TH, tyrosine hydroxylase; GFAP, glial fibrillary acidic protein; CNPase, 2',3'-cyclic nucleotide 3'-phosphodiesterase; NSC, neural stem cell; PNS, peripheral nervous system; BMSC, bone marrow MSC; ASC, adipose-derived stem cell; GDNF, glial cell line-derived neurotrophic factor; PLCL, poly DL-lactide-epsilon-caprolactone.

* Corresponding author.

E-mail address: erica.valencic@gmail.com (E. Valencic).

¹ These authors contributed equally to this work.

<http://dx.doi.org/10.1016/j.acthis.2015.02.005>

0065-1281/© 2015 Elsevier GmbH. All rights reserved.

Please cite this article in press as: Frausin S, et al. Wharton's jelly derived mesenchymal stromal cells: Biological properties, induction of neuronal phenotype and current applications in neurodegeneration research. Acta Histochemica (2015), <http://dx.doi.org/10.1016/j.acthis.2015.02.005>

Table 1
Factors used to obtain differentiation of MSCs from various sources into relevant cell types.

Differentiation into	Culture medium factors	References
Osteocytes	Ascorbic acid, β glycerol phosphate and dexamethasone	Pittenger et al. (1999)
Adipocytes	Dexamethasone, insulin, and isobutyl-methyl-zantine	Pittenger et al. (1999)
Chondrocytes	Transforming Growth Factor beta (TGF- β)	Baksh et al. (2007)
Cardiomyocytes	5-Azacytidine	Xu et al. (2004)
Endothelial cells	2% Fetal calf serum and vascular endothelial growth factor	Oswald et al. (2004)
Neurons	DMSO (di-methyl-sulf-oxide), butylated hydroxy-anisole (BHA), β -mercaptoethanol, forskolin, KCl, valproic acid and hydrocortisone	Woodbury et al. (2000) and Ishii et al. (1993)

as precursors of fibroblasts or stromal cells. MSCs represent a rare population (0.001–0.01% of nucleated cells) of adult human bone marrow cells, but they can also be identified in muscle, periosteum, adipose and other connective tissues (Castro-Malaspina et al., 1980; Pittenger et al., 1999).

Adult MSC can be readily isolated, exploiting their marked adhesive properties, and extensively expanded. These cells are heterogeneous, showing at least two subpopulations of cells in culture: small, spindle-shaped, rapidly self-renewing MSC and larger, slowly renewing MSC (Colter et al., 2001).

There is no specific marker for MSC, rather, the validation of MSC identity is based on a combination of phenotypic and functional characteristics. MSC express several surface proteins, including CD29, CD44, CD73, CD90, CD105, but low levels of HLA class I and undetectable hematopoietic markers such as CD14, CD34 and CD45, endothelial markers (CD31), HLA class II and costimulatory molecules (CD80, CD86) (Bobis et al., 2006; Conget and Minguell, 1999; Djouad et al., 2005; Fibbe and Noort, 2003; Gronthos et al., 2003; Pittenger et al., 1999).

The physiological function of MSCs in the bone marrow is to contribute to the formation of the hematopoietic stem cell (HSC) niche. Here, MSC preserve the HSC pool by maintaining HSC in a quiescent state (anti-proliferative activity) until, after appropriate stimulation, they differentiate and are released in the sinusoidal vascular system (Uccelli et al., 2008).

MSCs as a product for cell therapies: from immunomodulation to regenerative medicine

MSCs gained much attention about a decade ago, owing to their ability to differentiate into several cell types and to their immunosuppressive potential (Uccelli et al., 2006). Since then, it has been consistently shown that MSC can differentiate into different cell types of mesenchymal origin (adipocytes, chondrocytes and osteocytes) and can even trans-differentiate toward non-mesenchymal cell lineages, such as neurons, cardiomyocytes, endothelial cells (Baksh et al., 2007; Lu et al., 2006; Oswald et al., 2004; Pittenger et al., 1999; Woodbury et al., 2000; Xu et al., 2004) (Table 1).

The easy obtainment of large amounts of MSC from healthy donors, together with the differentiation ability of these cells have raised great expectations about their potential use in regenerative medicine (Taddio et al., 2012). In addition, it has become apparent

Box 1: Characteristics making MSC ideal candidates for cell therapies.

- Easily expanded from adult and fetal tissues
- Multilineage capabilities
- Immune privileged cells
- Immunomodulatory and anti-proliferative action
- Release of trophic factors
- Homing to damaged sites

that MSC may exert a beneficial trophic effect on injured tissues, even without necessarily replacing dying cells (Crigler et al., 2006; Shen et al., 2013). Thus, some characteristics of MSCs make these cells even more promising for the development of cell therapies (Box 1).

First, MSCs are poorly immunogenic (*i.e.* they escape detection by cells from the immune system thanks to the low expression of HLA molecules) and, depending on the preparation and on cell delivery route, can survive in recipients and exert their action for weeks (Kurtz, 2008).

Secondly, MSCs have been proven able of spontaneous migration towards the site of damage/inflammation when infused intravenously (Chamberlain et al., 2007). Even if most infused cells can be withheld in lungs, selective homing may allow concentrating the action of these cells just where it is needed, limiting possible undesired effects.

Third, it is increasingly clear that MSC have potent immunomodulatory properties. Indeed, it has been shown that these cells can inhibit proliferation of activated peripheral blood mononuclear cells both *in vitro* and *in vivo* (Uccelli et al., 2006). The immunomodulatory effect of MSC has been exploited in subjects who developed intractable graft *versus* host disease (GvHD) after haplo-identical hematopoietic stem cell transplantation (Dhir et al., 2014; Le Blanc and Ringden, 2007; Tyndall et al., 2007). Although there is no randomized clinical trial conclusively proving the advantage of MSC based therapies, this kind of treatment is currently used in many centers and several studies are ongoing to improve efficacy (Martin et al., 2014). In fact, based on preliminary clinical experiences and *in vitro* studies, there are several factors related both to the preparation of MSC and to the activation of immune system that can affect the outcome of MSC therapy. For example, activated natural killer (NK) cells are able to kill MSC (Spaggiari et al., 2006; Uccelli et al., 2008), while M1 macrophages, by producing IL-1 β , IL-6, TNF- α and IFN- γ , can inhibit the MSC growth *in vitro* (Freytes et al., 2013). On the other hand, the immunosuppressive potency of MSCs could be increased *in vitro* by the exposure to exogenous molecules (licensing), such as interferon-gamma (IFN- γ). For example, MSC that have been previously exposed, *in vitro*, to IFN- γ are resistant to NK-mediated lysis, probably because of an upregulation of HLA-I on their surface (Spaggiari et al., 2006; Uccelli et al., 2008).

In particular, we have previously shown that MSC are not able to suppress proliferation of pre-stimulated lymphocytes, while the IFN- γ treatment increases this activity (Valencic et al., 2010). In these experiments, the pre-stimulation of lymphocytes was meant to mimic what happens *in vivo*, in conditions such as GvHD, where the therapeutic use of MSC is proposed for patients with already active immune responses.

Overall, the combination of direct or indirect regenerative properties and immunomodulatory action can represent the added value of this therapy in conditions in which tissue damage is worsened by inflammatory or autoimmune mechanisms. For example, there is consistent evidence that hypoxic ischemic damage in newborns is greatly enhanced by secondary activation of an immune response to necrotic tissue, which can expand the effects




Fig. 1. Spontaneous migration of mesenchymal stromal cells from fragments of Wharton's jelly to the plastic well. The Wharton's jelly, after it has been diced in small fragments, is transferred on a plastic support (six-well plates) and incubated at 5% CO₂, 37 °C. After 10 days of undisturbed incubation the cells begin to migrate from the tissue to the surface well. Scale bar = 100 μm.

of the initial lesion (Barone et al., 1997; Emerich et al., 2002; Ladeby et al., 2005; Rothwell et al., 1997). Immune mechanisms with activation of macrophages and microglia have been shown to play a fundamental role also in neurodegenerative disorders (Streit et al., 1999). Thus the ability of MSCs to control immune activation and to provide trophic signals for tissue repair can be the basis of MSC based therapies in several conditions (van Velthoven et al., 2010).

Wharton's jelly mesenchymal stromal cells: easy and young

Wharton's jelly mesenchymal stromal cells (WJMSC) can easily be obtained in large numbers and could represent a valuable alternative to BM-derived cells also thanks to their younger origin (Batsali et al., 2013; McElreavey et al., 1991; Wang et al., 2004). Many protocols have been proposed to isolate cells from Wharton's jelly, depending on the possibility to remove umbilical arteries and vein, and on an enzymatic or mechanical dissection approach. The enzymatic treatment with collagenase, trypsin, or hyaluronidase disrupts the cellular matrix and then the isolated cells will be washed and cultured (Wang et al., 2004). More simply, the tissue can be mechanically dissociated into fragments (very small or a couple of centimeters depending on different protocols) and transferred in culture plates until the cells will migrate to the plastic bottom (La Rocca et al., 2009; Mitchell et al., 2003) (Fig. 1). Isolated cells or the fragments require medium such as low-glucose Dulbecco's modified Eagle medium containing fetal bovine serum or other supplement (platelet rich plasma) (Mitchell et al., 2003; Wang et al., 2004; Wen et al., 2014) (Fig. 2).

Similar to the bone marrow cells, umbilical cord, MSCs grow in adhesion on plastic supports where they typically exhibit a rhomboid-like and a fibroblastoid-like morphology. These two cell types differ in the amount of vimentin (mesenchymal marker) and pancytokeratin (ectodermal marker) (Colter et al., 2001).

Several studies have shown that WJMSCs can be differentiated into osteocytes, adipocytes, endothelial cells, chondrocytes and neural lineages (Chen et al., 2009; Karahuseyinoglu et al., 2007; Lu et al., 2006; Saben et al., 2014; Wang et al., 2004; Wu et al., 2007; Zuk et al., 2001). The immunomodulatory properties of WJMSCs were shown to be similar to bone marrow-derived MSCs (Weiss et al., 2006). Thanks to their strong proliferation potential and the large quantity in which they can be obtained, WJMSCs have recently




Fig. 2. Mesenchymal stromal cells at confluence, cultured in Dulbecco's modified eagle medium plus fetal bovine serum. They are heterogeneous showing at least two subpopulations: the first one displays a fibroblast-like morphology, is spindle-shaped and rapidly self-renewing (lower arrow, red); the second one exhibits a rhomboid-like morphology, is larger and slowly renewing (upper arrow, black). Scale bar = 100 μm.

emerged as a promising source of cells to be employed in the treatment of several neurological disorders (Zhou et al., 2012).

Neuron-like differentiation of WJMSCs

Under adequate stimulation, WJMSCs can differentiate into neuron-like cells *in vitro*, exhibiting both morphological and biochemical properties of neural cells and expressing typical neuronal proteins such as Nestin and Beta III Tubulin (Ishii et al., 1993; Woodbury et al., 2000) (Fig. 3). Likewise, WJMSCs can also differentiate into astrocytes and neurons *in vivo* after being exposed to peculiar culture media enriched with different factors and implanted into the mouse brain (Zhang et al., 2006).

Mitchell et al. (2003) were the first who observed neuronal differentiation of WJMSCs following a multi-step neuronal induction process. They used the protocol of Woodbury et al. (2000) for neuronal differentiation of the bone marrow MSCs. This protocol entails the use of a medium with low concentration of serum containing basic fibroblast growth factor (bFGF), butylated hydroxy-anisole (BHA), forskolin, KCl, valproic acid, hydrocortisone and di-methyl-sulf-oxide (DMSO, which increase cAMP levels). DMSO, in particular, proved to be capable of inducing the differentiation of several cell types towards a neuronal phenotype. Thus, differentiated neurons were detected or, more precisely, they were cells with neuronal morphology, expressing typical neuronal proteins (Woodbury et al., 2000).

To achieve neurons from WJSCs, different protocols have been adopted. Mitchell et al. (2003) found that WJMSCs can be induced to form neurons and glial cells after having been exposed to bFGF and low-serum media plus DMSO. It has been hypothesized that the DMSO may act *via* the regulation of protein kinase C pathway (Cheung et al., 2006), the down-regulation of c-myc gene, involved in cell growth and proliferation (Jiang et al., 2006), or both these mechanism combined.

Human WJMSCs differentiation may also occurs using retinoic acid (RA), nerve growth factor (NGF) and fetal calf serum (FCS), but the number of yielded neuronal cells may vary widely using different culture conditions.

Retinoic acid, a vitamin A derivative, is essential for the maintenance of normal cell growth and development and it promotes neuronal differentiation in various tissues, particularly in the nervous system, of both developing and adult animals, where it is present (Scintu et al., 2006).




Fig. 3. Unpublished observations: immunocytochemical expression of neuronal markers in cultured Wharton's jelly mesenchymal stromal cells predifferentiated (A,C,E,G) and differentiated (B,D,F,H). Human Wharton's jelly mesenchymal stromal cells appeared respectively positive and very positive to all neuronal specification markers such as Nestin (A,B), β III tubulin (C,D), NeuN (E,F). A limited number of Wharton's jelly mesenchymal stromal cells belonging to both treatment groups appeared weakly positive for the glial marker Glial Fibrillary Acid Protein (G,H), classically considered as a mature astrocytes marker, but also expressed by neural progenitors with not yet defined phenotype. These findings suggest that predifferentiation and differentiation protocols employed in this study have probably directed cells toward a neuronal-like rather than a glial-like specification. Scale bar = 100 μ m (A).

The limit of such approaches is given by the toxicity of the differentiating agents, which at high concentrations can induce widespread mortality in cell culture.

A method that does not make use of toxic molecules for the neuronal differentiation of WJMSCs requires them to be exposed to a neuronal conditioned medium (NCM), namely a medium obtained from cultures of neural stem cells or immature neurons, which is enriched in factors released by the cells themselves (Fu et al., 2004, 2006). Other strategies include treatment with a neuronal

induction medium (NIM) consisting mainly of brain-derived neurotrophic factor (BDNF) and low-serum media (Zhang et al., 2012) or with a cytokine mix that include NGF, epidermal growth factor (EGF), bFGF and BDNF together with forskolin. Even if these combinations may appear somewhat milder, they proved to be equally effective in inducing differentiation compared to the previous more toxic methods (Li et al., 2012).

Another possibility to induce differentiation of WJMSCs towards a specific neuronal phenotype may require co-culturing them with

some other types of cells. For example, Zhou et al. (2012) found that, when co-cultured with injured neural cells ($A\beta_{1-40}$ injured PC12 cells) in a Transwell® co-culture system, WJMSCs expressed neuronal markers at higher level than when other culture conditions were used.

Taken together, these findings suggest that human umbilical cord blood (Sanchez-Ramos, 2002) and Wharton's jelly (Karahuseyinoglu et al., 2007) contain cells that can be induced to neural antigenic and morphological phenotypes.

Neuron like phenotype in NSC-conditioned WJMSC

The marked differentiation capacity of mesenchymal stem cells has led the scientists to believe that they could be a good source of neural-like cells. As said before; different neural induction protocols have been developed; each giving rise to neural and/or glial-like cells. The differentiation level achieved after a neural induction has been addressed by analyzing the wide range of neural markers expressed by the differentiated WJMSCs both *in vitro* and *in vivo*. Several studies have therefore characterized the cells at various phases of differentiation or have compared various differentiation protocols.

Mitchell et al. (2003) showed that cells from Wharton's jelly are a rich source of primary cells that are readily expanded in culture and can be induced to form neurons and glia. In their study, they observed that, under the conditions imposed by the Woodbury's protocol, WJMSCs underwent profound changes in morphology, with the development of multiple dendrite-like, and single axon-like processes extending from the cell body, as well as granular structures reminiscent of Nissl substance in most cases (Guan et al., 2014; Mitchell et al., 2003). These changes in morphology were paralleled by a robust variation of the cell markers expressed. When tested for the presence of c-kit (a surface protein normally expressed in bone marrow stromal cells and hematopoietic stem cells), WJMSCs exhibited high expression levels which, however, were greatly diminished after their induction into neural cells. By contrast, steady increases in the expression of NFM, a neuron-specific intermediate filament, and of TuJ1, a class III neuron-specific β -tubulin, both markers for neural differentiation, were detected. To determine whether WJMSCs could become fully differentiated into a specific neuronal phenotype, the expression of the biosynthetic enzyme tyrosine hydroxylase (TH), a marker for catecholaminergic neurons, was investigated, together with that of GFAP and CNPase, markers for astrocytes and oligodendrocytes, respectively. TH was seen expressed in neurosphere-like colonies in fully induced cells, whereas GFAP-positive cells had a stellate morphology and lacked long process. By contrast, expression of CNPase was nearly identical in untreated and fully induced Wharton's jelly cells.

Hermann et al. (2004) went on and addressed the differentiation properties of the adult human bone marrow stromal cells. They characterized undifferentiated hMSCs, neuroprogenitor-like cells and clonogenic neural stem cells (NSCs) after differentiation, focusing their attention on mesodermal and neural markers and also the mRNA expression level of different proteins associated with the various stages of differentiation. In all cases they found a decreased expression of mesodermal markers and an increase of neural markers during the differentiation. The neuroprogenitor-like cells showed a strong increase in Nestin expression and a dosage of mRNA levels on neural-like cells reminiscent of mature neural cell type (GFAP, MBP, TUBB4/III, SNCA and TH) (Guan et al., 2014; Hermann et al., 2004).

Kogler et al. (2004) used cells derived from human cord blood to analyze their capacity to migrate, integrate and differentiate into

neural-like cells *in vivo* following implantation into the hippocampus of the intact adult rat. They identified cells widely distributed throughout the brain, indicating a high migratory activity *in vivo*. Immunohistochemistry revealed the highly differentiated morphology of implanted cells.

Potential of MSC in the treatment of peripheral nerve injury

The ultimate goal of research in the field of stem cells is to develop a feasible source of cells for transplantation in patients, the so-called *cell therapy*. This is a mere concept more than an actual therapeutic intervention; several steps need to be fulfilled before its realization, from practical and ethical point of view (Hyun et al., 2008).

Cell therapy follows different goals, based on the chosen target. In animal models of neurodegenerative diseases, the researchers have looked for two aspects when dealing with transplantation: the *cell replacement*, that is, the ability of the implanted cells to survive develop and integrate into the host tissue environment, so as to acquire the anatomical and functional properties of the cells lost as a result of the pathology and the *functional recovery* promoted by the transplanted cells. However, since many neurodegenerative diseases are progressive in nature, a third possible aspect researchers have to deal with is the ability of transplanted cells to promote *protection* of the host's tissue, in order to slow or reverse its degeneration.

In recent years, there has been much interest in the regeneration of the peripheral nervous system (PNS). Traumatic lesions of the peripheral nerves are now rather frequent and could be devastating. The strategies used for repairing these lesions have improved in last decades but they still show many limitations, and often result in an incomplete anatomical and functional restitution of the injured nerve. Thus, there is presently much interest towards the possibility to associate novel surgical procedures to the use of stem cells in order to improve nerve regeneration.

The nerve injury, with or without tissue loss, consists in the interruption of the nerve, with a consequent impossibility for the two parts to communicate, which in turn leads to a loss in functionality.

Repair may be achieved through spontaneous regeneration of severed axons, reconnection of the separate endings and reinnervation of the target tissues, although this is a rather remote event, resulting in very poor or no recovery.

In the absence of spontaneous reinnervation, as it happens, for example, when the injury creates a gap, surgical intervention with nerve repair becomes necessary. The aim of nerve repair is to help fibers regenerate with a minimal loss of tissue, so as to achieve a good recovery of sensory-motor functions. Nowadays, there are several surgical techniques that include the *direct repair* (Matsuyama et al., 2000), *neurotization* (Karol, 2003) and *nerve grafting* (Mafi et al., 2012). Most of these reconstruction strategies, however, have met with only modest success (Matsuyama et al., 2000; Rodriguez et al., 2012). Therefore, recent advances in nanotechnology and tissue engineering have attracted much interest to possibly provide feasible solutions for a broad range of applications in regenerative medicine and to help designing more effective strategies for anatomical and functional repair (Subramanian et al., 2009).

One of the most promising strategies that show good results is *tubulization*. The use of nerve guide has demonstrated strong potential and capacity to circumvent the many problems inherent to the old techniques (Luis et al., 2007). However, even *tubulization* has a series of limitations related, for example, to the size of the gap to be covered, the considerable diameter

of the scaffold and its slow reabsorption rate and, last but not least, the relatively modest anatomical and functional recovery observed.

For these reasons, there has recently been an increasing interest towards the possibility to enrich the nerve guides with cells (Daly et al., 2012).

The goal of the cell therapy in a PNS lesion is not cell replacement *per se* but, rather, the possibility to sustain the regeneration process. Thus, several studies have considered the use of different cell types, such as autologous Schwann cells, associated with the tubulization as a good method to improve the nerve regeneration (Udina et al., 2004). Unfortunately, however, these cells have a number of disadvantages associated with their use: their dissection is much invasive and painful, and their growth and expansion in culture is difficult and time-consuming (di Summa et al., 2010).

Recently, an alternative approach has considered the use of stem cells. These cells can create a good environment, by secreting factors that nourish, protect and stimulate both neuronal and non-neuronal cells involved in the regeneration of the severed nerve. Taken together, these features could help accelerating the regenerative process and may result in a better functional recovery (Ding et al., 2010; Kaewkhaw et al., 2011; Oliveira et al., 2010).

Owing to their peculiar functional characteristics (*i.e.* the marked capacity for differentiation, immunomodulation and growth support), MSCs are nowadays considered as one of the most suitable candidates for cell therapy in different diseases.

So far, either bone marrow-derived mesenchymal stem cells (BMMSCs) or adipose-derived stem cells (ASCs) have been tested preclinically. Both ASCs (Kingham et al., 2014) and BMSCs (Ishikawa et al., 2009) possess the ability to secrete multiple neurotrophic factors, including GDNF, NGF, NT-3 and BDNF (Kaewkhaw et al., 2011; Radtke et al., 2009). These cells have therefore been used in a number of studies in both differentiated and undifferentiated states in order to investigate their ability to promote peripheral nerve regeneration (Dezawa et al., 2001; Zorbakhsh et al., 2013).

However, there are several drawbacks that appear to greatly limit the suitability of these donor structures as a source of MSC: first, the procedure of cell isolation is invasive and painful; second MSCs normally occur at relatively low frequency in aspirates, thus many passages are needed to obtain sufficient numbers of cells to be used therapeutically, increasing the risk for cell contamination; third, MSC properties greatly vary with the donor's age. In this respect, WJMSC may represent a much better choice, as they are much easily attainable, exhibit excellent proliferative and differentiation potential, pose no ethical concern, and are of invariant, consistent, young age. However, only recently has interest emerged towards WJMSCs and their promising therapeutic potential (Aguilera et al., 2014; Batsali et al., 2013; Hsieh et al., 2013).

In our lab, we have recently investigated the promotion of the anatomical and functional regeneration of rat sciatic nerve after the formation of a 5 mm gap and the subsequent tubulization with a PLCL (poly DL-lactide-epsilon-caprolactone, Neurolac[®], courtesy of Polyganics, Groeningen, The Netherlands) copolyester tube. The guide was filled with hWJMSCs previously subjected to a predifferentiation treatment using media derived from NSCs culture.

Using a Walking track analysis test administered weekly over 20 weeks post-surgery, we have found significantly better functional recovery in the lesioned animals treated with hWJMSC-loaded PLCL guides, as compared to animals implanted with PLCL guide-only. Assessment of nerve retrograde transport capacity with fluorescent retrograde tracers, and post-mortem morphological analysis of the tubulized nerves confirmed the functional findings, as the




Fig. 4. Unpublished observations: photomicrographs showing the morphology of the regenerated rat sciatic nerve at about 20 weeks following tubulization, with the poly DL-lactide-epsilon-caprolactone guide containing no cells (A) or filled with human Wharton's jelly mesenchymal stromal cells (B). Note the virtually complete nerve reconstruction in (B), which also resulted in a better functional recovery than that achieved by the animal in (A) where nerve regrowth and organization appeared somewhat limited.

nerve treated with hWJMSC-loaded PLCL guides appeared better organized and structured (Fig. 4).

Potential of MSC in treatment of neurodegenerative diseases after transplantation

In recent years, several protocols have been developed for the transplantation of MSCs, which can be induced to transdifferentiate into cells of the nervous tissue *in vitro* (Sanchez-Ramos et al., 2000). Transplantation of MSCs, induced to express markers of neuronal differentiation, has shown a functional recovery in models of spinal dysfunction (Cho et al., 2009). Similar results were also obtained previously with undifferentiated MSCs derived from bone marrow (Cizkova et al., 2006) or from vessels of umbilical cord (Saporta et al., 2003), while none of these cell types exhibited a significant neuronal differentiation after transplantation. These results suggest that MSCs may release bioactive factors (Neuhuber et al., 2005) that influence regeneration, turnover and hematopoiesis. This influence was referred to as trophic because their bioactive factor secretion mediates the functional tissue outcome (Caplan and Dennis, 2006). When human mesenchymal stem cells engineered to secrete GDNF (glial cell line-derived neurotrophic factor) were transplanted into the muscles of rats with an ALS-like disease, motor function improved and disease progression was delayed (Suzuki et al., 2008). Compared with direct gene transfer, an advantage of cell-based gene delivery is that production of the trophic factor continues even if the disease process destroys the endogenous cells. Such mechanism has been proposed to underlie the ability of bone marrow-derived mesenchymal stem cells to prevent Purkinje cell death in a neurodegenerative mouse model of cerebellar ataxia (Jones et al., 2010). In this study, the observed increase in surviving Purkinje cells seemed to be the result of at least two processes, possibly responsible for this neuroprotection: the release of neurotrophic factors and, to a much lesser degree, cell fusion, without excluding the possibility of mechanical cell-cell trophic interactions (Jones et al., 2010).

Nowadays, clinical trials using MSCs are being carried out for a variety of important diseases such as stroke, multiple sclerosis, leukaemia and ALS. Clinical outcomes are variable, and generally show small improvements, but to date only few studies have been conducted over a long period of observation. There may be a direct




Fig. 5. Unpublished observations: Schematic diagram showing the effects upon survival of the implantation of human Wharton's jelly mesenchymal stromal cells into the lateral ventricle of mice exhibiting an amyotrophic lateral sclerosis-like phenotype. The average life span of SOD1G93A mice implanted with human Wharton's jelly mesenchymal stromal cells (158 ± 13 days) was significantly longer than that exhibited by non-implanted SOD1G93A mice (133 ± 7 days). In the best cell-treated cases, survival reached 171 days.

effect of the infused cells, but long-term clinical MSC engraftment is not yet routinely investigated (Otto and Wright, 2011).

Transplantation of MSC in experimental amyotrophic lateral sclerosis

Human MSC and mouse Bone Marrow cells delay disease onset and increase survival following delivery into the presymptomatic SOD1G93A mouse, an animal model of amyotrophic lateral sclerosis (ALS) (Corti et al., 2004; Ende et al., 2000).

Injected MSCs, however, scantily home to the central nervous system and engraft poorly. This provides support to the hypothesis that the restoring effects of transplanted cells is not due to cell replacement *per se* but, rather, it is associated with the production and release of circulating protective factors that may act both at the CNS and PNS levels. In fact it has been shown that implanted MSCs release a series of cytokines and chemokines with anti-inflammatory properties that could be responsible of the functional improvement of mouse models of motor neuron degenerative disorder (Bigini et al., 2011; Uccelli et al., 2012).

Along a similar line of evidence, we have recently observed that implantation of hWJMSCs in the lateral ventricle of SOD1G93A mice significantly delayed the onset of the severe functional impairments typically exhibited by these animals and extended their lifespan by about 30–40%, as opposed to non-transplanted mice (Fig. 5).

Again, and in keeping with previous findings (Bigini et al., 2011), the appearance of transplanted cells, never showing morphological features of mature neurons, nor expressing any neuronal markers either, strongly suggest that, as outlined above, they may act via the production and release of locally acting factors with protective and/or anti-inflammatory properties, rather than by replacement of degenerating neurons.

If so, it will be necessary to identify the substances produced and released by these cells upon their maintenance in culture, as well as upon their implantation in a diseased host. The possible characterization of these factors, cytokines and chemokines with trophic, disease-modifying, and anti-inflammatory properties could corroborate the hypothesis of neuroprotective immunomodulation as a promising strategy to decelerate the progression of neurodegenerative disease in some cases or improve the regeneration process in others.

Conclusion

The unique biological features exhibited by WJMSCs, associated to their easy isolation and handling, with no ethical or legal concerns, have raised expectations concerning their possible use as disease-modifying agents in cell-based therapies. Certainly, much preclinical work is yet to be done to fully unravel the restorative properties of WJMSCs when implanted in rodent models of nervous system damage or degeneration. Thus, the promising data obtained in early and ongoing studies, some of which reported and discussed in the present review, may represent an important theoretical framework, possibly leading to the eventual clinical application of WJMSCs for the treatment of various dysfunctions in the central and peripheral nervous system.

Conflict of interest

The authors declare that there are no conflict of interests.

Acknowledgements

Our own work has been supported by grants from Institute for Maternal and Child Health IRCCS Burlo Garofolo (Grant number RC#32/11), Trieste, Italy, the Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) (Grant number 20082H87WP) of Italy and the Kathleen Foreman Casali Foundation, Trieste, Italy.

References

- Aguilera V, Briceno L, Contreras H, Lamperti L, Sepulveda E, Diaz-Perez F, et al. Endothelium trans differentiated from Wharton's jelly mesenchymal cells promote tissue regeneration: potential role of soluble pro-angiogenic factors. *PLOS ONE* 2014;9:e111025.
- Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. *Stem Cells* 2007;25:1384–92.
- Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al. Tumor necrosis factor- α . A mediator of focal ischemic brain injury. *Stroke* 1997;28:1233–44.
- Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton's jelly of the umbilical

- cord: biological properties and emerging clinical applications. *Curr Stem Cell Res Ther* 2013;8:144–55.
- Bigini P, Veglianesi P, Andriolo G, Cova L, Grignaschi G, Caron I, et al. Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration. *Rejuvenation Res* 2011;14:623–39.
- Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: characteristics and clinical applications. *Folia Histochem Cytobiol* 2006;44:215–30.
- Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. *J Cell Biochem* 2006;98:1076–84.
- Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiarieri D, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. *Blood* 1980;56:289–301.
- Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells* 2007;25:2739–49.
- Chen MY, Lie PC, Li ZL, Wei X. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. *Exp Hematol* 2009;37:629–40.
- Cheung WM, Ng WW, Kung AW. Dimethyl sulfoxide as an inducer of differentiation in preosteoblast MC3T3-E1 cells. *FEBS Lett* 2006;580:121–6.
- Cho SR, Kim YR, Kang HS, Yim SH, Park CI, Min YH, et al. Functional recovery after the transplantation of neurally differentiated mesenchymal stem cells derived from bone marrow in a rat model of spinal cord injury. *Cell Transplant* 2009;18:1359–68.
- Cizkova D, Rosocha J, Vanicky I, Jergova S, Cizek M. Transplants of human mesenchymal stem cells improve functional recovery after spinal cord injury in the rat. *Cell Mol Neurobiol* 2006;26:1167–80.
- Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. *Proc Natl Acad Sci U S A* 2001;98:7841–5.
- Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. *J Cell Physiol* 1999;181:67–73.
- Corti S, Locatelli F, Donadoni C, Guglieri M, Papadimitriou D, Strazzer S, et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. *Brain* 2004;127:2518–32.
- Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neurogenesis. *Exp Neurol* 2006;198:54–64.
- Daly W, Yao L, Zeugolis D, Windebank A, Pandit A. A biomaterials approach to peripheral nerve regeneration: bridging the peripheral nerve gap and enhancing functional recovery. *J R Soc Interface* 2012;9:202–21.
- Dezawa M, Takahashi I, Esaki M, Takano M, Sawada H. Sciatic nerve regeneration in rats induced by transplantation of in vitro differentiated bone-marrow stromal cells. *Eur J Neurosci* 2001;14:1771–6.
- Dhir S, Slatter M, Skinner R. Recent advances in the management of graft-versus-host disease. *Arch Dis Child* 2014;99:1150–7.
- di Summa PG, Ingham PJ, Raffoul W, Wiberg M, Terenghi G, Kalbermatten DF. Adipose-derived stem cells enhance peripheral nerve regeneration. *J Reconstr Aesthet Surg* 2010;63:1544–52.
- Ding F, Wu J, Yang Y, Hu W, Zhu Q, Tang X, et al. Use of tissue-engineered nerve grafts consisting of a chitosan/poly(lactico-glycolic acid)-based scaffold included with bone marrow mesenchymal cells for bridging 50-mm dog sciatic nerve gaps. *Tissue Eng A* 2010;16:3779–90.
- Djouad F, Bony C, Hupl T, Uze G, Lahlou N, Louis-Plence P, et al. Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. *Arthritis Res Ther* 2005;7:R1304–15.
- Emerich DF, Dean RL 3rd, Bartus RT. The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? *Exp Neurol* 2002;173:168–81.
- Ende N, Weinstein F, Chen R, Ende M. Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). *Life Sci* 2000;67:53–9.
- Fibbe WE, Noort WA, Mesenchymal stem cells. hematopoietic stem cell transplantation. *Ann NY Acad Sci* 2003;996:235–44.
- Freytes DO, Kang JW, Marcos-Campos I, Vunjak-Novakovic G. Macrophages modulate the viability and growth of human mesenchymal stem cells. *J Cell Biochem* 2013;114:220–9.
- Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet* 1970;3:393–403.
- Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, et al. Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. *Stem Cells* 2006;24:115–24.
- Fu YS, Shih YT, Cheng YC, Min MY. Transformation of human umbilical mesenchymal cells into neurons in vitro. *J Biomed Sci* 2004;11:652–60.
- Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortessidis A, et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. *J Cell Sci* 2003;116:1827–35.
- Guan M, Xu Y, Wang W, Lin S. Differentiation into neurons of rat bone marrow-derived mesenchymal stem cells. *Eur Cytokine Netw* 2014;25:58–63.
- Hermann A, Gastl R, Liebau S, Popa MO, Fiedler J, Boehm BO, et al. Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. *J Cell Sci* 2004;117:4411–22.
- Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, et al. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. *PLOS ONE* 2013;8:e72604.
- Hyun I, Lindvall O, Ahrlund-Richter L, Cattaneo E, Cavazzana-Calvo M, Cossu G, et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. *Cell Stem Cell* 2008;3:607–9.
- Ishii K, Katayama M, Hori K, Yodoi J, Nakanishi T. Effects of 2-mercaptoethanol on survival and differentiation of fetal mouse brain neurons cultured in vitro. *Neurosci Lett* 1993;163:159–62.
- Ishikawa N, Suzuki Y, Dezawa M, Kataoka K, Ohta M, Cho H, et al. Peripheral nerve regeneration by transplantation of BMSC-derived Schwann cells as chitosan gel sponge scaffolds. *J Biomed Mater Res A* 2009;89:1118–24.
- Jiang G, Bi K, Tang T, Wang J, Zhang Y, Zhang W, et al. Down-regulation of TRRAP-dependent hTERT and TRRAP-independent CAD activation by Myc/Max contributes to the differentiation of HL60 cells after exposure to DMSO. *Int Immunopharmacol* 2006;6:1204–13.
- Jones J, Jaramillo-Merchan J, Bueno C, Pastor D, Viso-Leon M, Martinez S. Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia. *Neurobiol Dis* 2010;40:415–23.
- Kaewkhaw R, Scutt AM, Haycock JW. Anatomical site influences the differentiation of adipose-derived stem cells for Schwann-cell phenotype and function. *Glia* 2011;59:734–49.
- Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DO, et al. Biology of stem cells in human umbilical cord

- stroma: in situ and in vitro surveys. *Stem Cells* 2007;25:319–31.
- Karol AG. Peripheral nerves and tendon transfers. Selected reading in plastic surgery, vol. 9; 2003. p. 23.
- Kingham PJ, Kolar MK, Novikova LN, Novikov LN, Wiberg M. Stimulating the neurotrophic and angiogenic properties of human adipose-derived stem cells enhances nerve repair. *Stem Cells Dev* 2014;23:741–54.
- Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. *J Exp Med* 2004;200:123–35.
- Kurtz A. Mesenchymal stem cell delivery routes fate. *Int J Stem Cells* 2008;1:1–7.
- La Rocca G, Anzalone R, Corrao S, Magno F, Loria T, Lo Iacono M, et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. *Histochem Cell Biol* 2009;131:267–82.
- Ladeby R, Wirenfeltd M, Garcia-Ovejero D, Fenger C, Dissing-Olesen L, Dalmau I, et al. Microglial cell population dynamics in the injured adult central nervous system. *Brain Res Brain Res Rev* 2005;48:196–206.
- Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. *J Intern Med* 2007;262:509–25.
- Li J, Li D, Ju X, Shi Q, Wang D, Wei F. Umbilical cord-derived mesenchymal stem cells retain immunomodulatory and anti-oxidative activities after neural induction. *Neural Regen Res* 2012;7:2663–72.
- Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. *Haematologica* 2006;91:1017–26.
- Luis AL, Rodrigues JM, Lobato JV, Lopes MA, Amado S, Veloso AP, et al. Evaluation of two biodegradable nerve guides for the reconstruction of the rat sciatic nerve. *Biomed Mater Eng* 2007;17:39–52.
- Mafi P, Hindocha S, Dhital M, Saleh M. Advances of peripheral nerve repair techniques to improve hand function: a systematic review of literature. *Open Orthop J* 2012;6:60–8.
- Martin IP, Ireland H, Baldomero H, Passweg J. The survey on cellular engineered tissue therapies in Europe in 2012. *Tissue Eng A* 2014.
- Matsuyama T, Mackay M, Midha R. Peripheral nerve repair and grafting techniques: a review. *Neurol Med Chir* 2000;40:187–99.
- McElreavey KD, Irvine AI, Ennis KT, McLean WH. Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord. *Biochem Soc Trans* 1991;19:29S.
- Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, et al. Matrix cells from Wharton's jelly form neurons and glia. *Stem Cells* 2003;21:50–60.
- Neuhuber B, Timothy Himes B, Shumsky JS, Gallo G, Fischer I. Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations. *Brain Res* 2005;1035:73–85.
- Oliveira JT, Almeida FM, Biancalana A, Baptista AF, Tomaz MA, Melo PA, et al. Mesenchymal stem cells in a polycaprolactone conduit enhance median-nerve regeneration, prevent decrease of creatine phosphokinase levels in muscle, and improve functional recovery in mice. *Neuroscience* 2010;170:1295–303.
- Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. *Stem Cells* 2004;22:377–84.
- Otto WR, Wright NA. Mesenchymal stem cells: from experiment to clinic. *Fibrog Tissue Repair* 2011;4:20.
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143–7.
- Radtke C, Schmitz B, Spies M, Kocsis JD, Vogt PM. Peripheral glial cell differentiation from neurospheres derived from adipose mesenchymal stem cells. *Int J Dev Neurosci* 2009;27:817–23.
- Rodriguez R, Garcia-Castro J, Trigueros C, Garcia Arranz M, Menendez P. Multipotent mesenchymal stromal cells: clinical applications and cancer modeling. *Adv Exp Med Biol* 2012;741:187–205.
- Rothwell N, Allan S, Toulmond S. The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. *J Clin Invest* 1997;100:2648–52.
- Saben J, Thakali KM, Lindsey FE, Zhong Y, Badger TM, Andres A, et al. Distinct adipogenic differentiation phenotypes of human umbilical cord mesenchymal cells dependent on adipogenic conditions. *Exp Biol Med* 2014;239:1340–51.
- Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. *Exp Neurol* 2000;164:247–56.
- Sanchez-Ramos JR. Neural cells derived from adult bone marrow umbilical cord blood. *J Neurosci Res* 2002;69:880–93.
- Saporta S, Kim JJ, Willing AE, Fu ES, Davis CD, Sanberg PR. Human umbilical cord blood stem cells infusion in spinal cord injury: engraftment and beneficial influence on behavior. *J Hematother Stem Cell Res* 2003;12:271–8.
- Scintu F, Reali C, Pillai R, Badiali M, Sanna MA, Argioli F, et al. Differentiation of human bone marrow stem cells into cells with a neural phenotype: diverse effects of two specific treatments. *BMC Neurosci* 2006;7:14.
- Shen L, Zeng W, Wu YX, Hou CL, Chen W, Yang MC, et al. Neurotrophin-3 accelerates wound healing in diabetic mice by promoting a paracrine response in mesenchymal stem cells. *Cell Transplant* 2013;22:1011–21.
- Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood* 2006;107:1484–90.
- Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. *Prog Neurobiol* 1999;57:563–81.
- Subramanian A, Krishnan UM, Sethuraman S. Development of biomaterial scaffold for nerve tissue engineering: Biomaterial mediated neural regeneration. *J Biomed Sci* 2009;16:108.
- Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. *Mol Ther* 2008;16:2002–10.
- Taddio A, Biondi A, Piscianz E, Valencic E, Biagi E, Badolato R. From bone marrow transplantation to cellular therapies: possible therapeutic strategies in managing autoimmune disorders. *Curr Pharm Des* 2012;18:5776–81.
- Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. *Arthritis Res Ther* 2007;9:301.
- Uccelli A, Milanese M, Principato MC, Morando S, Bonifacino T, Vergani L, et al. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. *Mol Med* 2012;18:794–804.
- Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. *Eur J Immunol* 2006;36:2566–73.

- Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. *Nat Rev Immunol* 2008;8:726–36.
- Udina E, Rodriguez FJ, Verdu E, Espejo M, Gold BG, Navarro X. FK506 enhances regeneration of axons across long peripheral nerve gaps repaired with collagen guides seeded with allogeneic Schwann cells. *Glia* 2004;47:120–9.
- Valencic E, Piscianz E, Andolina M, Ventura A, Tommasini A. The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation. *Cytotherapy* 2010;12:154–60.
- van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ. Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. *Brain Behav Immun* 2010;24:387–93.
- Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. *Stem Cells* 2004;22:1330–7.
- Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. *Stem Cells* 2006;24:781–92.
- Wen Y, Gu W, Cui J, Yu M, Zhang Y, Tang C, et al. Platelet-rich plasma enhanced umbilical cord mesenchymal stem cells-based bone tissue regeneration. *Arch Oral Biol* 2014;59:1146–54.
- Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. *J Neurosci Res* 2000;61:364–70.
- Wu KH, Zhou B, Lu SH, Feng B, Yang SG, Du WT, et al. In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells. *J Cell Biochem* 2007;100:608–16.
- Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J, et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. *Exp Biol Med* 2004;229:623–31.
- Zarbaksh S, Moradi F, Joghataei MT, Bahktiari M, Mansouri K, Abedinzadeh M. Evaluation of the functional recovery in sciatic nerve injury following the Co-transplantation of Schwann and bone marrow stromal stem cells in rat. *Basic Clin Neurosci* 2013;4:291–8.
- Zhang H, Huang Z, Xu Y, Zhang S. Differentiation and neurological benefit of the mesenchymal stem cells transplanted into the rat brain following intracerebral hemorrhage. *Neurol Res* 2006;28:104–12.
- Zhang HT, Liu ZL, Yao XQ, Yang ZJ, Xu RX. Neural differentiation ability of mesenchymal stromal cells from bone marrow and adipose tissue: a comparative study. *Cytotherapy* 2012;14:1203–14.
- Zhou J, Tian G, Wang J, Luo X, Zhang S, Li J, et al. Neural cell injury microenvironment induces neural differentiation of human umbilical cord mesenchymal stem cells. *Neural Regen Res* 2012;7:2689–97.
- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 2001;7:211–28.